SCHEMBL2142999

SCHEMBL2142999

CCOC(COc1cc(C)c(C(=O)OC)cc1C)OCC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.37
▸ TAS1R3 Q7RTX0 5/20 0.36
▸ TAS1R1 Q7RTX1 5/20 0.36
▸ PDGFRB P09619 1/20 0.36
▸ FGFR1 P11362 1/20 0.36
▸ PDGFRA P16234 1/20 0.36
▸ FLT1 P17948 1/20 0.36
▸ FGFR3 P22607 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ KDM4E B2RXH2 3/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ HTT P42858 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ TAS1R2 Q8TE23 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MGLL Q99685 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21437253 0.88 KMT2A (0.36) TDP1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL24947165 0.80 TDP1 (0.48) TDP1TAS1R3TAS1R1KMT2AALDH1A1
SCHEMBL25883319 0.76 HPGD (0.36) TDP1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL31210707 0.76 TDP1 (0.47) TDP1KDM4EKMT2AALDH1A1HTT
SCHEMBL26669023 0.76 ABL1 (0.48) TDP1TAS1R3TAS1R1KMT2AALDH1A1
SCHEMBL31417579 0.75 SMN1; SMN2 (0.38) TDP1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL31417695 0.75 SMN1; SMN2 (0.38) TDP1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL21437919 0.75 TDP1 (0.38) TDP1KDM4EKMT2AALDH1A1HTT
SCHEMBL31411079 0.74 CA12 (0.39) ALDH1A1HTTLMNAMAPT
SCHEMBL2138587 0.74 VDR (0.34) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629271-B2 Compounds ASTRAZENECA AB (GB) 2014-01-14 — — US disclosed
US-8629271-B2 Compounds ASTRAZENECA AB (GB) 2014-01-14 — — US disclosed
US-8629271-B2 Compounds ASTRAZENECA AB (GB) 2014-01-14 — — US disclosed
US-20120322788-A1 Compouds PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2012-12-20 — — US disclosed
US-20120322788-A1 Compouds PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2012-12-20 — — US disclosed
US-20120322788-A1 Compouds PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2012-12-20 — — US disclosed
EP-2242759-B1 COMPOUNDS ASTRAZENECA AB (SE) 2012-09-12 — — EP disclosed
EP-2242759-B1 COMPOUNDS ASTRAZENECA AB (SE) 2012-09-12 — — EP disclosed
US-8148373-B2 Compounds ASTRAZENECA AB (SE) 2012-04-03 — — US disclosed
US-8148373-B2 Compounds ASTRAZENECA AB (SE) 2012-04-03 — — US disclosed
US-8148373-B2 Compounds ASTRAZENECA AB (SE) 2012-04-03 — — US disclosed
EP-2242759-A1 COMPOUNDS AstraZeneca AB (SE) 2010-10-27 — — EP disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 — — US disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 — — US disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 — — US disclosed
WO-2009098448-A1 COMPOUNDS ASTRAZENECA AB (SE) 2009-08-13 — — WO disclosed
WO-2009098448-A1 COMPOUNDS ASTRAZENECA AB (SE) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322788-A1 Compouds PKD1, SBDS, ABCB11 TDP1 4262/4885TAS1R3 2949/4885TAS1R1 1868/4885
US-20090298807-A1 Compounds PKD1, SLC10A1, ABCB11 TDP1 4473/4885TAS1R3 3341/4885TAS1R1 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback